Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,723.95
(
-1.69%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
106.58
(
5.89%
)
Bitcoin
71,040.13
(
-3.93%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 113621

Thursday, 07/28/2011 11:32:54 PM

Thursday, July 28, 2011 11:32:54 PM

Post# of 257257
BMY raised 2011 non-GAAP EPS guidance to $2.20-2.30 from the prior range of $2.08-2.18:

http://finance.yahoo.com/news/BristolMyers-Squibb-Delivers-bw-2995389373.html?x=0&.v=1

Non-GAAP EPS guidance for 2013 (first year post Plavix genericization) is unchanged at $1.95+ (#msg-47502391). There is no formal guidance for 2012.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now